BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37863068)

  • 21. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sophoridine suppresses macrophage-mediated immunosuppression through TLR4/IRF3 pathway and subsequently upregulates CD8
    Zhuang H; Dai X; Zhang X; Mao Z; Huang H
    Biomed Pharmacother; 2020 Jan; 121():109636. PubMed ID: 31733580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD25-expressing Th17 cells mediate CD8
    Lang C; Wang J; Chen L
    Exp Cell Res; 2017 Nov; 360(2):384-389. PubMed ID: 28942020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
    Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
    J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
    Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
    Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice.
    Küçükköse E; Heesters BA; Villaudy J; Verheem A; Cercel M; van Hal S; Boj SF; Borel Rinkes IHM; Punt CJA; Roodhart JML; Laoukili J; Koopman M; Spits H; Kranenburg O
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8
    Ma S; Sun B; Duan S; Han J; Barr T; Zhang J; Bissonnette MB; Kortylewski M; He C; Chen J; Caligiuri MA; Yu J
    Nat Immunol; 2023 Feb; 24(2):255-266. PubMed ID: 36658237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CHSY1 promotes CD8
    Sun G; Zhao S; Fan Z; Wang Y; Liu H; Cao H; Sun G; Huang T; Cai H; Pan H; Rong D; Gao Y; Tang W
    J Exp Clin Cancer Res; 2023 Sep; 42(1):248. PubMed ID: 37749638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-cell programming in pancreatic adenocarcinoma: a review.
    Seo YD; Pillarisetty VG
    Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8
    Liu C; Chikina M; Deshpande R; Menk AV; Wang T; Tabib T; Brunazzi EA; Vignali KM; Sun M; Stolz DB; Lafyatis RA; Chen W; Delgoffe GM; Workman CJ; Wendell SG; Vignali DAA
    Immunity; 2019 Aug; 51(2):381-397.e6. PubMed ID: 31350177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type I IFNs repolarized a CD169
    Liao J; Zeng DN; Li JZ; Hua QM; Huang CX; Xu J; Wu C; Zheng L; Wen WP; Wu Y
    Mol Ther; 2022 Feb; 30(2):632-643. PubMed ID: 34563673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases.
    Sullivan KM; Jiang X; Guha P; Lausted C; Carter JA; Hsu C; Labadie KP; Kohli K; Kenerson HL; Daniel SK; Yan X; Meng C; Abbasi A; Chan M; Seo YD; Park JO; Crispe IN; Yeung RS; Kim TS; Gujral TS; Tian Q; Katz SC; Pillarisetty VG
    Gut; 2023 Feb; 72(2):325-337. PubMed ID: 35705369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL; Linch SN; Kasiewicz MJ
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MGP promotes CD8
    Rong D; Sun G; Zheng Z; Liu L; Chen X; Wu F; Gu Y; Dai Y; Zhong W; Hao X; Zhang C; Pan X; Tang J; Tang W; Wang X
    Int J Biol Sci; 2022; 18(6):2345-2361. PubMed ID: 35414780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.
    McCaw TR; Li M; Starenki D; Cooper SJ; Liu M; Meza-Perez S; Arend RC; Buchsbaum DJ; Forero A; Randall TD
    Cancer Immunol Immunother; 2019 Feb; 68(2):175-188. PubMed ID: 30334128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8
    Zhang X; Wei Z; Yong T; Li S; Bie N; Li J; Li X; Liu H; Xu H; Yan Y; Zhang B; Chen X; Yang X; Gan L
    Nat Commun; 2023 Sep; 14(1):5653. PubMed ID: 37704614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
    Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
    Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.